<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	>
<channel>
	<title>Comments on: New Restrictions For Anemia Meds Are Looming</title>
	<atom:link href="http://www.pharmalot.com/2008/03/new-restrictions-for-anemia-meds-are-looming/feed" rel="self" type="application/rss+xml" />
	<link>http://www.pharmalot.com/2008/03/new-restrictions-for-anemia-meds-are-looming/</link>
	<description>News, Comment and Conversation</description>
	<pubDate>Fri, 10 Feb 2012 20:23:36 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.6.2</generator>
		<item>
		<title>By: New Restrictions For Anemia Meds Are Looming &#183; SmokeSignalz</title>
		<link>http://www.pharmalot.com/2008/03/new-restrictions-for-anemia-meds-are-looming/#comment-194618</link>
		<dc:creator>New Restrictions For Anemia Meds Are Looming &#183; SmokeSignalz</dc:creator>
		<pubDate>Fri, 07 Mar 2008 13:46:48 +0000</pubDate>
		<guid isPermaLink="false">http://www.pharmalot.com/2008/03/new-restrictions-for-anemia-meds-are-looming/#comment-194618</guid>
		<description>[...] Health Blog wrote an interesting post today onHere&#8217;s a quick excerpt An FDA advisory committee will meet next Thursday to review the latest evidence of risk for cancer patients who are treated with widely used anemia meds - Amgen’s Aranesp and Epogen, Johnson &#38; Johnson’s Procrit. The same panel met last May, but since then, new data was given the FDA from several studies showing increased risks of death or faster tumor growth. (Look here). So Wall Street is betting that the drugs, known as ESAs, may face added restrictions. One possibility - the FDA may advise [...]</description>
		<content:encoded><![CDATA[<p>[...] Health Blog wrote an interesting post today onHere&#8217;s a quick excerpt An FDA advisory committee will meet next Thursday to review the latest evidence of risk for cancer patients who are treated with widely used anemia meds - Amgen’s Aranesp and Epogen, Johnson &#38; Johnson’s Procrit. The same panel met last May, but since then, new data was given the FDA from several studies showing increased risks of death or faster tumor growth. (Look here). So Wall Street is betting that the drugs, known as ESAs, may face added restrictions. One possibility - the FDA may advise [...]</p>
]]></content:encoded>
	</item>
</channel>
</rss>

<!-- Dynamic Page Served (once) in 0.147 seconds -->
<!-- Cached page served by WP-Cache -->

